Выбор антигипертензивного препарата и профилактика поражения почек при АГ в свете новых европейских рекомендаций
- Авторы: Гиляревский С.1,2, Голшмид М.1, Кузьмина И.2
-
Учреждения:
- РМАПО
- Институт скорой помощи им Н.В. Склифосовского
- Выпуск: Том 24, № 9 (2013)
- Страницы: 2-6
- Раздел: Статьи
- URL: https://journals.eco-vector.com/0236-3054/article/view/115741
- ID: 115741
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Рассматриваются современные подходы к выбору антигипертензивного препарата для профилактики поражения почек и улучшения прогноза, основанные на доказательной информации и мнении экспертов, изложенном в новом варианте Европейских клинических рекомендаций.
Ключевые слова
Полный текст
Об авторах
С. Гиляревский
РМАПО; Институт скорой помощи им Н.В. Склифосовского
Email: sgilarevsky@rambler.ru
доктор медицинских наук, профессор
М. Голшмид
РМАПОкандидат медицинских наук
И. Кузьмина
Институт скорой помощи им Н.В. Склифосовскогокандидат медицинских наук
Список литературы
- Diercks G., vanBoven A., Hillege J. et al. The importance of microalbuminuria as a cardiovascular risk indicator: a review // Can. J. Cardiol. - 2002; 18: 525-35.
- Kovesdy C., Lott E., Lu J. et al. Outcomes associated with microalbuminuria: effect modification by chronic kidney disease // J. Am. Coll. Cardiol. - 2013; 61: 1626-33.
- Klausen K., Borch-Johnsen K., Feldt-Rasmussen B. et al. Very low levels of microalbuminuriaare associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes // Circulation. -2004; 110: 32-5.
- Gerstein H., Mann J., Yi Q. et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondi- abetic individuals // JAMA. - 2001; 286: 421-6.
- Arnlov J., Evans J., Meigs J. et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study // Circulation. - 2005; 112: 969-75.
- Zoccali C., Mallamaci F. Albuminuria in the normal range: the lower is not the better // J. Am. Coll. Cardiol. - 2013; 61: 1634-6.
- Mann J., Schmieder R., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial // Lancet. - 2008; 372: 547-53.
- Kidney Disease Improving Global Outcomes. Clinical practice guideline for the management of blood pressure in chronic kidney disease // Kidney Int. Suppl. - 2013; 2: 337-414.
- Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2013; 31: 1281-357.
- Lea J., Greene T., Hebert L. et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension // Arch. Int. Med. - 2005; 165: 947-53.
- de Zeeuw D., Remuzzi G., Parving H. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy // Circulation. - 2004; 110: 921-7.
- Schmieder R., Mann J., Schumacher H. et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease // Am. Soc. Nephrol. - 2011; 22: 1353-64.
- ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. - 2007; 370: 829-40.
- Mogensen C. Urinary albumin excretion in early and long-term juvenile diabetes // Scand. J. Clin. Lab. Invest. - 1971; 28: 183-93.
- Viberti G., Hill R., Jarrett R. et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus // Lancet. - 1982; 1: 1430-2.
- de Zeeuw D., Parving H., Henning R. Microalbuminuria as an early marker for cardiovascular disease // J. Am. Soc. Nephrol. - 2006; 17: 2100-5.
- Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. - 2007; 25: 1105-87.
- Standards of medical care in diabetes - 2009 // Diabetes Care. - 2009; 32 (1): 13-61.
- Brenner B., Cooper M., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. - 2001; 345: 861-9.
- Lewis E., Hunsicker L., Clarke W. et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. - 2001; 345: 851-60.
- Ruggenenti P., Fassi A., Ilieva A. et al. Preventing microalbuminuria in type 2 diabetes // N. Engl. J. Med. - 2004; 351: 1941-51.
- Haller H., Ito S., Izzo J. et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N. Engl. J. Med. - 2011; 364: 907-17.
- FDA Drug Safety Communication: Safety Review Update of Benicar (olmesartan) and cardiovascular events. [4/14/2011]. URL: www.fda.gov/Drugs/ DrugSafety/ucm251268.htm
- Savarese G., Costanzo P., Cleland J. et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure // J. Am. Coll. Cardiol. - 2013; 61: 131-42.
- Moher D., Liberati A., Tetzlaff J. et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement // J. Clin. Epidemiol. - 2009; 62: 1006-12.
- van Vark L., Bertrand M., Akkerhuis K. et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients // Eur. Heart. J. - 2012; 33: 2088-97.
- Lv J., Perkovic V., Foote C. et al. Antihypertensive agents for preventing diabetic kidney disease // Cochrane Database Syst. Rev. - 2012; 12: CD004136. doi: 10.1002/14651858.CD004136.pub3.
Дополнительные файлы
